# Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct07108504/  
OnCo record `nct07108504` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of gemcitabine and LM-302 in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT07108504 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 30 participants, started 2025-08-10 and due to reach its primary completion in 2026-08-10. Interventions recorded: Gemcitabine; LM-302. Conditions listed: Pancreatic Cancer; Chemotherapy Effect. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic ductal adenocarcinoma (PDAC) not amenable to curative treatment". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07108504
- Phase: 2
- Setting: An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of LM-302 Combined With Gemcitabine as Second-line Treatment for CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07108504: https://clinicaltrials.gov/study/NCT07108504

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [LM-302](https://onco.cc/drugs/lm-302/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07108504.json